Healthcare
Regenicin, Inc.(RGIN)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +6.3%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regenicin, Inc. (RGIN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +6.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +6.3%, free cash flow -13.2% with operating margin 0.0% and ROIC 12.1%. Stock Foundry combines RGIN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on May 15, 2023, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +6.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 May 15, 2023 | โ | +0.0% | +0.0% | +0.0% |
2023 Feb 13, 2023 | โ | +0.0% | +0.0% | +0.0% |
2023 Jan 13, 2023 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGIN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGIN Max Drawdown
-80.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGIN and SPY.
Company Overview
Regenicin, Inc.
Other OTC
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
- Leadership
- Randall E. McCoy
- IPO Date
- Nov 16, 2009
- Employees
- 3
- Street Address
- 10 High Court
- Mailing
- Little Falls, NJ, 07424
- Region
- Little Falls, NJ, US
- Reporting Currency
- USD
- Investor Line
- 973 557 8914
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +6.3%
- Free Cash Flow
- -13.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 11.9%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.